Evidence map›Paper›PMID 35351135›Full record

ArticleBMC medicine2022

Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients.

Emily Toscano-Guerra, Mónica Martínez-Gallo, Iria Arrese-Muñoz, Anna Giné, Noelia Díaz-Troyano, Pablo Gabriel-Medina, Mar Riveiro-Barciela, Moisés Labrador-Horrillo, Fernando Martinez-Valle, Adrián Sánchez Montalvá and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Association of the androgens with COVID-19 prognostic outcomes: a systematic review.Archives of public health = Archives belges de sante publique · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. SARS-CoV-2, fertility and assisted reproduction.Human reproduction update · 2023
    Review
  7. Testosterone and Covid-19: An update.Reviews in medical virology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Emily Toscano-GuerraBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Mónica Martínez-GalloImmunology Division, Vall d'Hebron Hospital, Barcelona, Spain. mmartinez@vhebron.net.
Iria Arrese-MuñozImmunology Division, Vall d'Hebron Hospital, Barcelona, Spain.
Anna GinéBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Noelia Díaz-TroyanoBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Pablo Gabriel-MedinaBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Mar Riveiro-BarcielaInternal Medicine Service, Vall d'Hebron Hospital, Barcelona, Spain.
Moisés Labrador-HorrilloInternal Medicine Service, Vall d'Hebron Hospital, Barcelona, Spain.
Fernando Martinez-ValleInternal Medicine Service, Vall d'Hebron Hospital, Barcelona, Spain.
Adrián Sánchez MontalváInfectious Diseases Department, International Health and Tuberculosis Unit National Referral Centre for Tropical Diseases, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Manuel Hernández-GonzálezImmunology Division, Vall d'Hebron Hospital, Barcelona, Spain.
Ricardo Pujol BorrellImmunology Division, Vall d'Hebron Hospital, Barcelona, Spain.
Francisco Rodríguez-FriasBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Roser FerrerBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Timothy M ThomsonUniversidad Peruana Cayetano Heredia, Lima, Perú. titbmc@ibmb.csic.es.
Rosanna PaciucciBiochemistry Service, Vall d'Hebron Hospital, Autonomous University of Barcelona (UAB), Barcelona, Spain. rpaciucci@vhebron.net.ORCID http://orcid.org/0000-0001-5651-5933
Universitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ESConsejo Superior de Investigaciones Científicas · ESVall d'Hebron Institut de Recerca · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR 1411 GRCAgència de Gestió d'Ajuts Universitaris i de Recerca 2020PANDE00048Consejo Superior de Investigaciones Científicas CSIC-COV19-006, CSIC-COV19-201Conselleria d'Educació, Investigació, Cultura i Esport PID-107139RB-C21Instituto de Salud Carlos III COVID-19_00416Instituto de Salud Carlos III PI18/00346Ministerio de Ciencia, Innovación y Universidades RTI2018-096055-B-I00
6 · The paper itself

Abstract

backgroundSARS-CoV-2 infection portends a broad range of outcomes, from a majority of asymptomatic cases to a lethal disease. Robust correlates of severe COVID-19 include old age, male sex, poverty, and co-morbidities such as obesity, diabetes, and cardiovascular disease. A precise knowledge of the molecular and biological mechanisms that may explain the association of severe disease with male sex is still lacking. Here, we analyzed the relationship of serum testosterone levels and the immune cell skewing with disease severity in male COVID-19 patients.

methodsBiochemical and hematological parameters of admission samples in 497 hospitalized male and female COVID-19 patients, analyzed for associations with outcome and sex. Longitudinal (in-hospital course) analyses of a subcohort of 114 male patients were analyzed for associations with outcome. Longitudinal analyses of immune populations by flow cytometry in 24 male patients were studied for associations with outcome.

resultsWe have found quantitative differences in biochemical predictors of disease outcome in male vs. female patients. Longitudinal analyses in a subcohort of male COVID-19 patients identified serum testosterone trajectories as the strongest predictor of survival (AUC of ROC = 92.8%, p < 0.0001) in these patients among all biochemical parameters studied, including single-point admission serum testosterone values. In lethal cases, longitudinal determinations of serum luteinizing hormone (LH) and androstenedione levels did not follow physiological feedback patterns. Failure to reinstate physiological testosterone levels was associated with evidence of impaired T helper differentiation and augmented circulating classical monocytes.

conclusionsRecovery or failure to reinstate testosterone levels is strongly associated with survival or death, respectively, from COVID-19 in male patients. Our data suggest an early inhibition of the central LH-androgen biosynthesis axis in a majority of patients, followed by full recovery in survivors or a peripheral failure in lethal cases. These observations are suggestive of a significant role of testosterone status in the immune responses to COVID-19 and warrant future experimental explorations of mechanistic relationships between testosterone status and SARS-CoV-2 infection outcomes, with potential prophylactic or therapeutic implications.

Indexed as

COVID-19AndrogensFemaleHumansLuteinizing HormoneMaleSARS-CoV-2TestosteroneAndrogensLuteinizing HormoneTestosteroneCOVID-19Immune phenotypeLongitudinalSurvivalTestosterone

Identifiers

PMID35351135
PMCPMC8963401
OpenAlexW4225254264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.